Once the transaction is closed, Exelixis will control 100% of GamaMabs' AMHR2 franchise technology, including all assets related to GamaMabs' monoclonal antibody drug product, murlentamab (GM-102).

AMHR2 is a target for novel oncology therapies, as demonstrated in anti-AMHR2 monoclonal antibody clinical trials. AMHR2 is expressed in ovarian, endometrial, renal, liver, colon, and lung tumors.

GM-102 is well tolerated but yields only modest efficacy, therefore GamaMabs discontinued development in early 2021. Although it does not have plans to move murlentamab forward, Exelixis is encouraged by the potential of the AMHR2 target as it pursues the further discovery and development of novel biologics, especially antibody drug conjugates.

GamaMabs is eligible for additional completion and milestone payments after closing.

Exelixis licenses antibody panel from WuXi Biologics
Exelixis and WuXi Biologics have entered into an exclusive license agreement to support the expansion of Exelixis' oncology pipeline.

Exelixis, Adagene partner on masked ADCs
Exelixis and Adagene have signed a license agreement to generate masked versions of monoclonal antibodies from Exelixis' preclinical pipeline for the...

Exelixis enters collaborations for antibody drug conjugates
Exelixis has entered into two separate partnerships with Catalent and NBE Therapeutics for the discovery and development of multiple antibody-drug conjugates...